Elevation Oncology Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid Tumors

-- EO-1022 is comprised of seribantumab, an anti-HER3 monoclonal antibody, and an MMAE payload –-- Following recently signed global license agreement with Synaffix, EO-1022 leverages the company's GlycoConnect® and HydraSpace® ADC technologies for glycan site-specific conjugation and SYNstatin E™ linker-payload --– Elevation Oncology expects to present EO-1022 preclinical data in 1H 2025 and to file an IND application in 2026 –BOSTON, Dec. 12, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an ...